Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, ...

Novo Nordisk is under investor pressure for transparency regarding their obesity drug CagriSema, after trial results disappointed. Patients report weight loss but side effects like nausea. Investors ...

This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...

Centene beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by strength in its commercial health ...

--"The 2025 forecast will command the most attention in the annual accounts," Hansen said. "The addition of production capacity will continue to be the guiding principle for the full-year forecast." ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

LOS ANGELES, CA / ACCESS Newswire / February 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

SO WHAT: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.